{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:25:21Z","timestamp":1786116321716,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"DOI":"10.1007\/s10096-026-05613-2","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:33:58Z","timestamp":1786008838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal safety of amikacin compared with ceftriaxone in patients treated for urinary tract infection: an observational cohort study"],"prefix":"10.1007","author":[{"given":"Iris","family":"Zohar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvir","family":"Melloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Satra-Shenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debby","family":"Ben David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"5613_CR1","doi-asserted-by":"publisher","first-page":"e030266","DOI":"10.1136\/bmjopen-2019-030266","volume":"10","author":"P Shamsrizi","year":"2020","unstructured":"Shamsrizi P, Gladstone BP, Carrara E, Luise D, Cona A, Bovo C et al (2020) Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. BMJ Open 10:e030266. https:\/\/doi.org\/10.1136\/bmjopen-2019-030266","journal-title":"BMJ Open"},{"key":"5613_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/jac\/dkm318","volume":"60","author":"MJ Schwaber","year":"2007","unstructured":"Schwaber MJ, Carmeli Y (2007) Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60:913\u2013920. https:\/\/doi.org\/10.1093\/jac\/dkm318","journal-title":"J Antimicrob Chemother"},{"key":"5613_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/jac\/dkz457","volume":"75","author":"I Zohar","year":"2020","unstructured":"Zohar I, Schwartz O, Yossepowitch O, David SSB, Maor Y (2020) Aminoglycoside versus carbapenem or piperacillin\/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. J Antimicrob Chemother 75:458\u2013465. https:\/\/doi.org\/10.1093\/jac\/dkz457","journal-title":"J Antimicrob Chemother"},{"key":"5613_CR4","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1093\/jac\/dkaa148","volume":"75","author":"M Elbaz","year":"2020","unstructured":"Elbaz M, Zadka H, Weiss-Meilik A, Ben-Ami R (2020) Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. J Antimicrob Chemother 75:2307\u20132313. https:\/\/doi.org\/10.1093\/jac\/dkaa148","journal-title":"J Antimicrob Chemother"},{"key":"5613_CR5","doi-asserted-by":"publisher","first-page":"dlaf126","DOI":"10.1093\/jacamr\/dlaf126","volume":"7","author":"A Cahan","year":"2025","unstructured":"Cahan A, Peleg R, Sorek N, Brosh-Nissimov T (2025) Aminoglycoside versus \u03b2-lactam treatment for urosepsis-a retrospective cohort study. JAC Antimicrob Resist 7:dlaf126. https:\/\/doi.org\/10.1093\/jacamr\/dlaf126","journal-title":"JAC Antimicrob Resist"},{"key":"5613_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/jac\/13.suppl_a.9","volume":"13","author":"G Kahlmeter","year":"1984","unstructured":"Kahlmeter G, Dahlager JI (1984) Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 13:9\u201322 Suppl A. https:\/\/doi.org\/10.1093\/jac\/13.suppl_a.9","journal-title":"J Antimicrob Chemother"},{"key":"5613_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0002-9343(96)80074-x","volume":"101","author":"J Koo","year":"1996","unstructured":"Koo J, Tight R, Rajkumar V, Hawa Z (1996) Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med 101:177\u2013183. https:\/\/doi.org\/10.1016\/s0002-9343(96)80074-x","journal-title":"Am J Med"},{"key":"5613_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1128\/AAC.39.3.650","volume":"39","author":"DP Nicolau","year":"1995","unstructured":"Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R (1995) Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39:650\u2013655. https:\/\/doi.org\/10.1128\/AAC.39.3.650","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5613_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/ki.1988.83","volume":"33","author":"HD Humes","year":"1988","unstructured":"Humes HD (1988) Aminoglycoside nephrotoxicity. Kidney Int 33(4):900\u2013911. https:\/\/doi.org\/10.1038\/ki.1988.83","journal-title":"Kidney Int"},{"key":"5613_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","volume":"69","author":"D Yahav","year":"2019","unstructured":"Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R et al (2019) Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis 69:1091\u20131098. https:\/\/doi.org\/10.1093\/cid\/ciy1054","journal-title":"Clin Infect Dis"},{"key":"5613_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/heartjnl-2013-304588","volume":"100","author":"D Radovanovic","year":"2014","unstructured":"Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O et al (2014) Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002\u20132012. Heart 100:288\u2013294. https:\/\/doi.org\/10.1136\/heartjnl-2013-304588","journal-title":"Heart"},{"issue":"4","key":"5613_CR12","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179\u2013c184. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract"},{"key":"5613_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1532-5415.1985.tb04615.x","volume":"33","author":"PA Gabow","year":"1985","unstructured":"Gabow PA, Hutt DM, Baker S, Craig SR, Gordon JB, Lezotte DC (1985) Comparison of hospitalization between nursing home and community residents. J Am Geriatr Soc 33:524\u2013529. https:\/\/doi.org\/10.1111\/j.1532-5415.1985.tb04615.x","journal-title":"J Am Geriatr Soc"},{"key":"5613_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1128\/AAC.25.4.438","volume":"25","author":"IH Patel","year":"1984","unstructured":"Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ (1984) Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 25:438\u2013442. https:\/\/doi.org\/10.1128\/AAC.25.4.438","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05613-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05613-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05613-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:33:59Z","timestamp":1786008839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05613-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":14,"alternative-id":["5613"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05613-2","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and national and institutional standards and approved by the Edith Wolfson medical center Ethics Committee - approval number 0069-22-WOMC.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for written informed consent was waived due to the retrospective, observational nature of the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author YM received honoraria for lectures and participation in advisory boards from Medison, GSK, MSD, Pfizer, Tzamal and Takeda, and travel support from Pfizer. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}